Radiotherapy and Antiangiogenic TM in Lung Cancer

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2002 Mar 16

PMID 11896571

Citations 23

Authors

Mohamed K Khan

Meredith W Miller

Jeremy Taylor

Navkiranjit K Gill

Robert D Dick

Kenneth van Golen

George J Brewer

Sofia D Merajver

Affiliations

Soon will be listed here.

Abstract

Tetrathiomolybdate (TM) is a potent nontoxic orally delivered copper complexing agent under development for the last several years for the treatment of Wilson's disease. It has been shown to block angiogenesis in primary and metastatic tumors. Therefore, the combination of cytotoxic radiotherapy (RT) and antiangiogenic TM could target both the existing tumor and the tumor microvasculature in a comprehensive strategy. Using a Lewis lung high metastatic (LLHM) carcinoma mouse tumor model, we demonstrate that the combination of TM and RT is more effective than either used as monotherapy. We also show that their therapeutic effects are additive, with no additional toxicity. We show that TM has no significant cytotoxicity in vitro against LLHM tumor cells, further supporting the antiangiogenic mechanism for its action.

Citing Articles

Copper in Gynecological Diseases.

Conforti R, Delsouc M, Zorychta E, Telleria C, Casais M Int J Mol Sci. 2023; 24(24).

PMID: 38139406 PMC: 10743751. DOI: 10.3390/ijms242417578.

The Antitumor Impact of Combining Hepatic Artery Ligation With Copper Chelators for Liver Cancer.

Zeng N, Wang Y, Wan Y, Wang H, Li N Clin Med Insights Oncol. 2023; 17:11795549231204612.

PMID: 38023286 PMC: 10666691. DOI: 10.1177/11795549231204612.

Regulatory roles of copper metabolism and cuproptosis in human cancers.

Wang Z, Jin D, Zhou S, Dong N, Ji Y, An P Front Oncol. 2023; 13:1123420.

PMID: 37035162 PMC: 10076572. DOI: 10.3389/fonc.2023.1123420.

High-Affinity Cu(I)-Chelator with Potential Anti-Tumorigenic Action-A Proof-of-Principle Experimental Study of Human H460 Tumors in the CAM Assay.

Heuberger D, Wolint P, Jang J, Itani S, Jungraithmayr W, Waschkies C Cancers (Basel). 2022; 14(20).

PMID: 36291910 PMC: 9600560. DOI: 10.3390/cancers14205122.

Current Biomedical Use of Copper Chelation Therapy.

Baldari S, Di Rocco G, Toietta G Int J Mol Sci. 2020; 21(3).

PMID: 32041110 PMC: 7037088. DOI: 10.3390/ijms21031069.

References

Fajardo L, Berthrong M . Vascular lesions following radiation. Pathol Annu. 1988; 23 Pt 1:297-330. View

Shing Y . Heparin-copper biaffinity chromatography of fibroblast growth factors. J Biol Chem. 1988; 263(18):9059-62. View

Badet J, Soncin F, Guitton J, Lamare O, Cartwright T, Barritault D . Specific binding of angiogenin to calf pulmonary artery endothelial cells. Proc Natl Acad Sci U S A. 1989; 86(21):8427-31. PMC: 298295. DOI: 10.1073/pnas.86.21.8427. View

Ho Y, Liu H, Duh J, Chen R, Ho W, Jeng J . Induction of apoptosis by S-nitrosoglutathione and Cu2+ or Ni2+ ion through modulation of bax, bad, and bcl-2 proteins in human colon adenocarcinoma cells. Mol Carcinog. 1999; 26(3):201-11. View

Brewer G, DICK R, Grover D, LeClaire V, Tseng M, Wicha M . Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res. 2000; 6(1):1-10. View

Kerbel R . Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000; 21(3):505-15. DOI: 10.1093/carcin/21.3.505. View

Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer J . Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000; 60(5):1326-31. View

Browder T, Butterfield C, Kraling B, Shi B, Marshall B, OReilly M . Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000; 60(7):1878-86. View

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin D . Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000; 105(8):R15-24. PMC: 517491. DOI: 10.1172/JCI8829. View

10.

Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175(3):409-16. PMC: 1355186. DOI: 10.1097/00000658-197203000-00014. View

11.

Schosinsky K, Lehmann H, BEELER M . Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem. 1974; 20(12):1556-63. View

12.

Fajardo L . The unique physiology of endothelial cells and its implications in radiobiology. Front Radiat Ther Oncol. 1989; 23:96-112. DOI: 10.1159/000416574. View

13.

Brem S, Tsanaclis A, Zagzag D . Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery. 1990; 26(3):391-6. DOI: 10.1097/00006123-199003000-00003. View

14.

Watanabe T, Seno M, Sasada R, Igarashi K . Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol Endocrinol. 1990; 4(6):869-79. DOI: 10.1210/mend-4-6-869. View

15.

Brem S, Zagzag D, Tsanaclis A, Gately S, Elkouby M, Brien S . Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol. 1990; 137(5):1121-42. PMC: 1877678. View

16.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

17.

Engleka K, Maciag T . Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation. J Biol Chem. 1992; 267(16):11307-15. View

18.

Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O . Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994; 269(9):6271-4. View

19.

OReilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M . Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79(2):315-28. DOI: 10.1016/0092-8674(94)90200-3. View

20.

Yoshida D, Ikeda Y, Nakazawa S . Suppression of tumor growth in experimental 9L gliosarcoma model by copper depletion. Neurol Med Chir (Tokyo). 1995; 35(3):133-5. DOI: 10.2176/nmc.35.133. View